BEIJING, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Dehaier Medical Systems Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), which develops, assembles, markets and sells medical devices and wearable sleep respiratory products in China, today announced that its sleep respiratory solution systems have been adopted by an additional 26 major hospitals and 4 medical examination centers in Beijing, Tianjin, Shanxi, Hebei, Anhui, Hubei, Shandong, Inner Mongolia, and Gansu provinces. This, combined with the 22 hospitals and 6 medical examination centers announced last month, brings the total count of hospitals and medical examination centers equipped with the Company's wearable sleep respiratory solution systems to 58 in 14 provinces and cities throughout the country. The Company's wearable sleep respiratory solution features a full range of products and services, including working stations, software, watch-sized sleep diagnostic devices, and PPG sensors. Dehaier's product line enables Obstructive Sleep Apnea Syndrome ("OSAS") diagnosis, CPAP treatment, curative effect evaluation, and other related services.

Mr. Ping Chen, Chief Executive Officer of Dehaier, stated, "We are very pleased to see our sleep respiratory business making further inroads into the emerging OSAS treatment and device market in China, which is projected to grow at a compound annual growth rate of 16.5% between 2011 and 2017 and reach $19.7 billion by 2017. As we continue to roll out our nationwide sales and marketing plan, we expect the strong momentum for our wearable sleep respiratory solution systems to continue, allowing us to penetrate between 100 and 150 hospitals and medical examination centers by the end of 2014. Looking ahead, we are increasingly optimistic about the prospects of our sleep respiratory business and view it as an important catalyst, both near- and long- term, for our ongoing transformation into a more sustainable and scalable medical solutions provider."

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including medical devices and wearable sleep respiratory products. The company develops and assembles its self-branded medical devices and sleep respiratory products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), HEYER (Germany) and Timesco (UK). Dehaier's technology is based on six patents and eleven software copyrights. More information may be found at

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, fulfillment of bids and contracts, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
CONTACT: For more information, please contact:                  Dehaier Medical Systems Limited         Janice Wang         +86 10-5166-0080                  Weitian Investor Relations         Tina Xiao         917-609-0333